A high incidence of initial infection with human papillomavirus (HPV) was previously reported in a cohort of 608 women monitored at 6-month intervals for 3 years. Risk factors for subsequent infections with different HPV types and whether antibodies against HPV-16 virus-like particles (VLPs) protected against these infections were examined. Subsequent infections with HPV are very common. Seventy percent of women acquired a different HPV type within 24 months of the initial infection. Risk factors included being nonwhite, having an increased number of male sex partners, and having had a new male sex partner. Use of oral contraceptive pills was protective. A sustained high level of IgG antibody to HPV-16 VLPs was associated with reduced risk for subsequent infection with HPV-16 and its genetically related types (i.e., HPV-31, -33, -35, -52, and -58).
The high prevalence of human papillomavirus (HPV) and its causal relationship with cervical neoplasia make this sexually transmitted agent an important public health problem [1] [2] [3] [4] [5] . We have previously reported that, in a cohort of young women, 43% of the subjects who were HPV-negative at baseline acquired an infection within 3 years after follow-up [3] . Because 150 different HPV types infect the genital area [6] , questions remain whether a woman's risk of acquiring a subsequent infection with a different HPV type is altered after the initial infection, what risk factors are involved in acquisition of new types, and whether host immunity protects against subsequent infection. Such information is valuable for prevention and control of HPV infection and, hence, ultimately, cervical neoplasia through development of educational programs as well as strategic vaccine interventions.
Subjects and Methods
Study population. From Rutgers University, New Brunswick, New Jersey, 608 female students were recruited through campuswide advertisements. The mean (‫ע‬SD) age of subjects was 20 ‫ע‬ years, 81% were in the first or second year of college, and the 3 ethnic distribution was 57% white, 13% Hispanic, 12% black, 10% Asian, and 8% other. At baseline, 13% of the subjects had never had vaginal sex, the median number of lifetime male sex partners was 3, and the HPV prevalence was 26% [7] . Subjects were followed at 6-month intervals for a maximum of 3 years, with a median of 5 visits per subject. The majority of the follow-up visits (89%) were completed within 5-7 months after the previous visit. At each visit, a self-administered questionnaire, which obtained demographic, behavioral, and lifestyle information since the last visit, was completed, and a cervicovaginal lavage sample was obtained. Blood samples for serum preparation were collected at the annual visits initially and at the 6-month visits in the last year of implementation of the study; 70% of consecutive blood samples were obtained within 9-15 months.
Laboratory methods for detection of HPV DNA and antibodies to HPV-16 virus-like particles (VLPs).
Exfoliated cervicovaginal cells were obtained by lavage for HPV determination and typing by polymerase chain reaction (PCR) and Southern blot hybridization, as described elsewhere [7, 8] . HPV PCR products that did not hybridize to any type-specific probes were considered to represent "uncharacterized" HPV types. A sample was considered to be HPV positive if either PCR or Southern blot yielded a positive result and HPV negative if results of both assays were negative. HPV types determined by PCR and Southern blot were combined for analyses.
HPV-16 VLPs were heterologously expressed in Trichoplusia ni (High Five; Invitrogen) cells infected with recombinant baculovirus, which encodes the complete L1/L2 open-reading frames downstream of the polyhedrin promoter (provided by John Schiller, Na- tional Cancer Institute and the National Institutes of Health). A modification of the protocol described by McCarthy et al. [9] was used for VLP purification. Highly purified HPV-16 VLPs were used in a modified polymer ELISA for antipapillomavirus antibody detection [10] . In brief, 96-well ELISA plates (PolySorp; Nalgene Nunc International) were coated overnight with 50 ng/well VLPs. Subsequently, the plates were washed 6 times with 1ϫ PBS and 0.05% Tween 20, blocked for 3 h with 1ϫ PBS and 0.5% polyvinyl alcohol, and washed 3 times. The plates were then incubated with human serum (diluted 1:100 in blocking buffer, 100 mL/well) for 1 h at 37ЊC. After 10 washings with 1ϫ PBS and 0.05% Tween 20, 100 mL of goat anti-human IgG (1:10,000) or IgA (1:5000), horseradish peroxidase-conjugated (Jackson Immunoresearch Laboratories), diluted in 1ϫ PBS, 0.5% polyvinyl alcohol, 0.8% polyvinylpyrrolidone, and 0.025% Tween 20, was added to each well and incubated for 30 min at 37ЊC. After 10 washings, 100 mL of 2,2 -azino-di [3-ethyl- 16 VLPs, the seropositivity cutoff points were chosen to maximize the specificity among the women who were HPV-16 DNA negative. For the ELISA for IgG antibody to HPV-16 VLPs, the cutoff point of log OD уϪ0.79 gave a sensitivity of 47% and specificity of 100%. If 74 women from an additional study who were HPV-16 DNA-positive and had cervical intraepithelial neoplasia were included in the ROC analyses, sensitivity of the ELISA for IgG to HPV-16 VLPs increased to 65% without altering the specificity. For the ELISA for IgA to HPV-16 VLPs, the cutoff point of log OD уϪ1.00 gave a sensitivity of 24% and specificity of 100%. Serum samples were assayed in duplicate, and the serostatus was determined by applying the cutoff point to the mean log OD. Systemic IgA antibody to HPV-16 VLPs appears to have a lower circulating titer than does IgG, because the geometric mean OD level at baseline was 0.014 for IgA and 0.082 for IgG; hence, there was a disparity in sensitivity of the assays for the 2 types of antibodies and the lower seroprevalence of IgA to HPV-16 VLPs at baseline than that of IgG (6.3% vs. 14.1%).
Statistical analyses. About 5% of the subjects who tested positive at any time for HPV DNA had "skip patterns" in type-that is, negativity for a specific type flanked by positivity. It is difficult to distinguish whether the skip was because of resolution and repeat acquisition of the same type or fluctuation of virus load below the PCR detection limit. Nevertheless, skip patterns were rare, and the latter scenario was assumed to be the cause of such patterns. Therefore, subsequent HPV infection refers to acquisition of a different type that was not detected in any previous visits. Multiple HPV types detected in a visit were treated as 1 episode of infection, and only additional types that were detected in different visits were considered separate episodes of incident infection.
The analyses were based on 247 subjects who had an initial HPV infection, which was either detected at baseline or acquired during follow-up, and had at least 1 follow-up visit afterwards. The entry point to analysis was the first visit in which HPV DNA was detected. An event occurred when a different HPV type was detected in a subsequent visit. The cumulative probabilities of acquiring an incident infection with a different HPV type after the first infection were estimated by the Kaplan-Meier method. Time-dependent proportional hazards regression analysis for multiple failure data was used to identify independent risk factors for incident HPV infection with different types. Subjects were allowed to have multiple failure data (i.e., multiple subsequent visits with different HPV types). Time to event could be calculated as time since the first HPV-positive visit or time since the last failure; we used the latter. That is, we analyzed time to the second infection since the initial infection, time to the third infection since the second infection, etc., restarting the event time clock when a new infection occurred. This approach was justified by the data shown in table 1 and is explained in detail below. Time-dependent Cox regression analysis was also used to identify risk factors associated with subsequent infection with an HPV-16-related type (i.e., HPV-16, -31, -33, -35, -52, or -58) after the first HPV infection. Because only a few subjects had different HPV-16-related types detected in multiple visits, single failure data were analyzed. The 6 HPV-16-related types belong to 1 phylogenetic clade on the basis of the L1 sequences, which encode the major capsid protein that is necessary and sufficient to generate VLPs (see online phylogenetic tree at http://hpv-web.lanl.gov/COMPENDIUM_PDF/ 97PDF/1/Intro97.pdf). This grouping allowed us to examine whether humoral responses to HPV-16 VLPs would confer protection against subsequent infection with HPV-16 or its genetically related types.
The majority of serum samples were obtained annually, and data on IgG and IgA serostatus were not available for each 6-month visit. Serostatus was analyzed as a time-dependent variable indicating the cumulative number of times the ELISA for IgG or IgA yielded positive results in all previous visits. Persistent seropositivity was defined as detectable antibodies in у2 visits (i.e., 112 months, given that most serum samples were collected annually). The absence of antibodies and transient antibodies did not influence the risk of subsequent infection, so subjects who had antibodies in 0 or 1 visit were grouped together in analysis. There was a strong correlation between seropositivity for IgG and IgA to HPV-16 VLPs: 25 (69.4%) of 36 baseline samples positive for IgA were also ). Therefore, we also examined the cumulative number of P p .085 times a subject had a high IgG level (log OD 1Ϫ0.326, median among seropositive samples, which was equivalent to a titer of 1400-800).
In the survival analyses, the time of the subsequent HPV infection was estimated as the midpoint between visits. This method can under-or overestimate risks depending on whether the baseline hazard function is increasing or decreasing over time. To examine the sensitivity of our results to the midpoint assumption, we compared the results presented here with those from similar Cox proportional hazards regression analyses when time of infection was assumed to occur at the time of the visit. Little change in the regression coefficients was observed. We further examined the baseline hazard function by graphically smoothing the point estimates of hazard; there was little change in the hazard over the follow-up period. Furthermore, we also examined if there was heterogeneity in event rates across subjects, as is often the case in repeated-event survival analyses; inclusion of a random effect (frailty) showed little change in either point estimates or confidence intervals. Finally, the assumption of proportional hazards was checked through weighted residuals and was found to hold for all covariates [11] .
The statistical software packages SAS (SAS Institute), Stata (StataCorp), and S-Plus (MathSoft) were used for data analyses [12] [13] [14] . All P values presented are 2-sided.
Results
The 24-month cumulative incidences for subsequent HPV infection were 70.2% among 247 women who had at least 1 follow-up visit after their initial HPV infection, 71.6% among 141 women who were HPV-positive at baseline, and 67.3% among 106 women whose initial infection was detected during follow-up. Women who had a prevalent infection at baseline could be likely to have been exposed to different HPV types before enrollment and have acquired type-specific immunity, which would then alter their risk for subsequent HPV infection. However, the data showed that, in this cohort of young women whose time span of sexual experience was relatively short, risk for infection with additional HPV types was not different regardless of whether the initial infection was detected at baseline ( , log rank test). P p .682 Table 1 shows the risk of subsequent infection given that HPV infection with different types was already detected in 1-3 previous visits. The highest risk for subsequent infection occurred within 6 months (i.e., in the next visit) after the last infection. Among the 247 women who had an initial HPV infection, the incidence of subsequent infection was 41% in the first 6 months, compared with 15% and 8% in the second and third 6-month periods, respectively. Among the 120 women who had 2 previous visits with HPV infection, 45% acquired a third infection within 6 months since the second infection, and the incidence declined to 13% and to 6% in the next two 6-month periods. A similar pattern was seen for incidence of a fourth infection among 55 women in whom HPV infections were detected in 3 previous visits. Because of this phenomenon, when multiple subsequent infections were analyzed in Cox regression models, as described below, we analyzed time to event since last failure rather than time since entry to analysis (i.e., initial HPV infection). That is, the event time clock was restarted after an event occurred, and we analyzed risk for acquiring an additional type since the last incident infection. Table 2 shows risk factors associated with subsequent infection with a different HPV type for 247 subjects who had a previous HPV infection. Among the 160 subjects who had at least 1 subsequent infection, the median number of events per subject was 1 (maximum, 5 events), and 18% of them had у3 events. Risk factors included being nonwhite, an increased number of male sex partners in the previous 7-12 months (i.e., between the last visit and the visit before it), and having had a new male sex partner for р24 months since the last visit. Use of oral contraceptive pills since the last visit was protective and associated with a reduced risk for subsequent HPV infection. Persistent seropositivity of IgG to HPV-16 VLPs for у2 visits alone, without the presence of persistent IgA antibodies, was not a significant risk factor for subsequent infection. Subjects who had persistence of both IgG and IgA had a 53% reduced risk for subsequent infection, compared with that for those who had persistent IgG only (relative risk ; ).
[RR] p .47 P p .070 Because the presence of IgA to HPV-16 VLPs was associated with a high IgG level, the protective effect of such dual persistence could be attributed to a strong IgG response. We then replaced the variables concerning persistent seropositivity of IgA and IgG in the regression model, with a variable indicating the cumulative number of times a subject had a high level of IgG (log OD 1Ϫ0.326). Women with high levels of IgG to HPV-16 VLPs in у2 previous visits had a lower risk for subsequent HPV infection than did those without ( ; ). RR p .49 P p .037 Two potential confounders were adjusted for in these regression models: whether the subject had prevalent HPV infection or antibodies to HPV-16 VLPs at baseline and the number of different HPV types detected in previous visits. They were considered as markers for previous exposure to and hence immunity against HPV types other than HPV-16.
To determine whether antibodies to HPV-16 VLPs were associated with a reduced risk for acquisition of non-HPV-16-related types, additional analyses were performed with the outcome defined as subsequent infection with a non-HPV-16-related type only (i.e., exclusion of incident infections with HPV-16, -31, -33, -35, -52, or -58). There were 145 subjects who had у1 event. After the 7 risk factors presented in table 2 were adjusted, subjects who had persistent seropositivity to both IgG and IgA antibodies had a 32% reduced risk for subsequent infection with a non-HPV-16-related type, compared with that for those who had persistent IgG only ( ; ). RR p .68 P p .328 Having had high levels of IgG to HPV-16 VLPs in у2 previous visits showed a moderate protective effect ( ; RR p .57 P p ). . 131 We then examined whether antibodies to HPV-16 VLPs conferred group-specific protection against HPV-16-related types (HPV-16, -31, -33, -35, -52, or -58). Table 3 shows that none Downloaded from https://academic.oup.com/jid/article-abstract/186/6/737/2191057 by guest on 18 February 2019 of the 12 women with persistent seropositivity to both IgG and IgA and none of the 15 women with high levels of IgG to HPV-16 VLPs in у2 previous visits had incident infection with an HPV-16-related type. Of the 247 subjects who had an initial HPV infection, 65 had an HPV-16-related type in the 1st positive visit. Those who had a persistent infection for у2 visits had the lowest risk for acquiring another HPV-16-related type (table 4) . Women who had a type-specific persistent infection with a non-HPV-16-related type also had a reduced risk, although to a lesser extent.
Discussion
We have reported elsewhere that, in this cohort of college women, 34% of the subjects who were HPV-negative at baseline acquired an initial infection within 24 months [3] . We now demonstrate that there was a 70% chance that a woman would acquire a subsequent infection with a different HPV type within 24 months of the initial infection. Given that 150 HPV types infect the genital tract and HPV is the most prevalent sexually transmitted disease among young women [3, 6] , it is not surprising that women with a risk profile are susceptible to exposure and hence acquisition of HPV initially and subsequently. This risk profile is largely defined by behavior, because highrisk sexual activities were associated with increased incidences of both initial and subsequent HPV infections in this cohort of women. Risk factors for initial HPV infection were described elsewhere [3] . In this report, we found the following sexual behavioral risk factors for subsequent infection with a different HPV type: having had a new regular male partner for a duration of р24 months and an increased number of vaginal sex partners in the previous 7-12 months (i.e., between the last 2 visits). The latter factor and the observation that the highest incidence of infection with a new HPV type occurred within 6 months of the last infection suggest that some of the subsequent types may not necessarily be a new acquisition but rather a delay in detection, perhaps related to the time required for the virus to replicate in cervicovaginal cells after infection and reach a detectable level.
Use of oral contraceptives was associated with a reduced risk for subsequent infection. It was not explained by the lack of condom use, because adjustment for this variable did not alter the relationship. It is unlikely that oral contraceptives would lower the detectability of HPV, because they were associated with an increased prevalence of HPV infection in some studies [15] [16] [17] . Also, glucocorticoid and progesterone response elements have been found in the viral genome, suggesting that steroid hormones may promote expression of the viral genes [18, 19] . Oral contraceptives may induce transcription of the viral capsid gene and increase seroreactivity of the host [20] . Increased seropositivity to HPV-16 VLPs among users of oral contraceptives was reported in a study elsewhere [20] . In our cohort, we also found use of oral contraceptives at the time of blood draw to be associated with seroconversion to IgG to HPV-16 VLPs ( ) as well as IgA ( ) (au-RR p 2.39 RR p 1.81 thors' unpublished data). Some oral contraceptive users could actually have neutralizing antibodies not detected by our current ELISA that accounted for some protective effects. Use of oral contraceptives was correlated with having a stable, longterm relationship with a sex partner in this cohort. Although this latter factor was adjusted for in the regression model, the possibility still exists that oral contraceptive pill use was an indicator of some low-risk sexual behaviors that were not measured or adequately controlled for in this study.
Seropositivity for IgA antibody to HPV-16 VLPs appeared to be correlated with the host ability to mount a strong IgG response. The proportions of subjects with persistently high IgG levels for у2 visits increased from 6.7% among subjects without IgA to 51.5% among those who were IgA positive at only 1 visit and further to 90.2% among those who were IgA positive for у2 visits. Hence, the observation that continual presence of both systemic IgG and IgA to HPV-16 VLPs was associated with a decreased risk for subsequent HPV infection, whereas persistent IgG alone without persistent IgA did not, could be attributed to intense IgG levels. In fact, a high IgG level (OD 10.47 or titer 1400-800) for у2 visits showed an association with reduced risk for subsequent infection similar to that of dual persistence of IgG and IgA. Therefore, subjects with persistent IgG alone without persistent IgA could have a low IgG response that was not sufficient to confer protection.
This study showed that persistent antibodies to HPV-16 VLPs were associated with reduced risk for subsequent HPV infection. The association was the strongest for HPV-16-related types and the weakest for unrelated types. For the subjects who had persistently high levels of IgG to HPV-16 VLPs for у2 visits, their incidence and relative risk for subsequent infection with an HPV-16-related type was virtually zero. When both HPV-16-related and -unrelated types were included as the outcome, the protective effect of antibodies to HPV-16 VLPs was greatly reduced, and the relative risk increased to 0.49. When HPV-16-related types were removed from the outcome and only non-HPV-16-related types were considered, the protective effect of antibodies to HPV-16 VLPs became negligible, and the relative risk increased further to 0.57. Experimental studies have shown consistently that VLP antibodies have neutralizing effects that protect the host from infection [21] , but the neutralization is mainly type-specific [22] [23] [24] . Therefore, the modestly reduced risk for subsequent infection with non-HPV-16-related types was unlikely to be attributed to cross-type protection conferred by antibodies to HPV-16 VLPs. Dual persistence of IgG and IgA to HPV-16 VLPs and high levels of persistent IgG could be markers for the host's ability to produce strong, protective, type-specific immune responses against HPV types to which the host was exposed previously. We considered past HPV exposure in data analyses, for example, by including the number of HPV types detected in previous visits in the regression model. Nevertheless, confounding due to the presence of non-HPV-16 VLP antibodies could not be controlled for effectively unless VLP antibodies to the most common genital HPV types were analyzed simultaneously.
The HPV-16 VLP antibody-associated reduced risk for subsequent infection was the most dramatic for the HPV-16 phylogenetic group. Some studies have reported cross-protection between HPV-16 and HPV-33 [23, 24] . Hence, in the analyses confined to HPV types of a phylogenetic group, type-specific as well as some cross-type protections were observed. Moreover, data from seroepidemiologic studies suggest that there is crossreactivity between antibodies to HPV-16 and its related types [25, 26] . The ELISA for antibody to HPV-16 VLPs may detect cross-reactive antibodies to HPV-16-related types but not antibodies to unrelated types. Some of the protective effects of antibodies to HPV-16 VLPs on subsequent infection with HPV-16-related types could be due to cross-reactive antibodies.
Other than persistent antibodies, we also found type-specific persistent infection, particularly with a phylogenetically related type, to have a protective effect on subsequent infection with an HPV-16-related type. Persistent infection may favor development and stability of immune responses, be it humoral or cell-mediated.
In summary, once a woman has been infected with HPV, subsequent infections with different HPV types are very common. Immune protection against HPV appears to require a sustained strong IgG response facilitated by type-specific persistent infection. However, given the facts that HPV infection is generally transient, not all persons develop antibodies, and those who seroconvert do not necessarily have long-lasting immunity [3, 27, 28] , acquired immune protection against HPV after natural infection is likely to occur in a subset of persons.
